Skip to main content
Livermore
Livermore
ZHEN

Boxer Capital Management, LLC

SEC CIK
0002018299
Latest filing
Aug 14, 2026

The latest 13F from Boxer Capital Management, LLC covers Q2 2026 (filed Aug 14, 2026): 63 long positions worth $1.33B. The top 10 holdings make up 65.1% of the portfolio, and the largest is Tango Therapeutics, Inc. (TNGX) at 25.6%. Livermore has 10 filings on Form 13F from this institution, going back to Q4 2024.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
12
Est. +$100.3M
Added
17
Est. +$239.6M
Reduced
1
Est. −$2.55M
Sold out
3
Est. −$26.9M

Top 5 holdings

Share of this quarter's portfolio value

  1. TNGXTango Therapeutics, Inc.
    25.6%$340.0MHistory
  2. RVMDRevolution Medicines, Inc.
    7.1%$93.6MHistory
  3. ABVXAbivax S.A.
    6.1%$80.6MHistory
  4. QUREuniQure N.V.
    5.2%$69.2MHistory
  5. KODKodiak Sciences Inc.
    4.3%$57.6MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. ABVXAbivax S.A.
    +$54.0MAddedHistory
  2. QTTBQ32 Bio Inc.
    +$40.1MNewHistory
  3. QUREuniQure N.V.
    +$38.8MAddedHistory
  4. REPLReplimune Group, Inc.
    +$31.1MAddedHistory
  5. CELCCelcuity Inc.
    +$20.0MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. QUREuniQure N.V.
    +3.79 pp1.4% → 5.2%History
  2. ABVXAbivax S.A.
    +3.15 pp2.9% → 6.1%History
  3. QTTBQ32 Bio Inc.
    +3.02 pp0.0% → 3.0%History
  4. REPLReplimune Group, Inc.
    +2.14 pp1.2% → 3.3%History
  5. DFTXDefinium Therapeutics, Inc.
    +2.05 pp1.5% → 3.5%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. TERNTerns Pharmaceuticals, Inc.
    −$19.8MSold outHistory
  2. SLNOSoleno Therapeutics Inc
    −$6.70MSold outHistory
  3. ALLOAllogene Therapeutics, Inc.
    −$2.55MReducedHistory
  4. KALVKalVista Pharmaceuticals, Inc.
    −$410.7KSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. TERNTerns Pharmaceuticals, Inc.
    −2.60 pp2.6% → 0.0%History
  2. SLNOSoleno Therapeutics Inc
    −0.88 pp0.9% → 0.0%History
  3. ALLOAllogene Therapeutics, Inc.
    −0.64 pp0.9% → 0.2%History
  4. KALVKalVista Pharmaceuticals, Inc.
    −0.05 pp0.1% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$1.33B
+$566.1M (+74.3%) vs. prior quarter
Positions
63
+9 vs. prior quarter
Top 10 concentration
65.1%
Top 10 as share of value
Turnover
2.8%
Q2 2026, one quarter
Average holding period
5.0 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2024), so positions held before then are understated.

13F filings by quarter

7 quarters, going back to Q4 2024. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $1.33B (Q2 2026)

Q4 2024: $1.17BQ1 2025: $332.5MQ2 2025: $198.7MQ3 2025: $313.7MQ4 2025: $456.9MQ1 2026: $761.7MQ2 2026: $1.33B
Q4 2024Q2 2026
13F filings of Boxer Capital Management, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202663$1.33BTNGXRVMDABVXvs. Q1 2026SEC
Q1 2026May 15, 202654$761.7MTNGXKODRVMDvs. Q4 2025SEC
Q4 2025Feb 17, 202645$456.9MTNGXRVMDKODvs. Q3 2025SEC
Q3 2025Feb 17, 2026Amended34$313.7MTNGXQURERVMDvs. Q2 2025SEC
Q2 2025Feb 17, 2026Amended20$198.7MTNGXRVMDREPLvs. Q1 2025SEC
Q1 2025Feb 17, 2026Amended28$332.5MRVMDNUVLMRUSvs. Q4 2024SEC
Q4 2024Feb 14, 202560$1.17BRVMDSWTXNUVL–SEC

13D and 13G filings

Companies where Boxer Capital Management, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

2 companies, largest stake first.

Companies where Boxer Capital Management, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
QTTBQ32 Bio Inc.13G13.30%3.15M sharesNewJul 10, 20261 filingJul 10, 2026SEC
SRZNSurrozen, Inc.13G/A8.90%1.04M shares+2.23 ppfrom 6.67%May 15, 20262 filingsAug 14, 2026SEC

Latest filings

18 filings on file made by Boxer Capital Management, LLC or listing it as a reporting person, newest first.

Schedule 13D and 13G filings by Boxer Capital Management, LLC
CompanyFiled (ET)FilerFormStakeChangeEvent dateFiling
SRZNSurrozen, Inc.Aug 14, 20264:05 PM ETBoxer Capital Management, LLCand 3 others13G/A8.90%1.04M shares+2.23 ppfrom 6.67%Jun 30, 2026SEC
QTTBQ32 Bio Inc.Jul 10, 20264:34 PM ETBoxer Capital Management, LLCand 3 others13G13.30%3.15M sharesNewJun 30, 2026SEC
SRZNSurrozen, Inc.May 15, 20264:01 PM ETBoxer Capital Management, LLCand 3 others13G6.67%766.3K sharesNewMar 31, 2026SEC
TILInstil Bio, Inc.May 15, 20257:34 PM ETBoxer Capital Management, LLCand 5 others13G/A1.20%80.1K shares–Below 5%May 9, 2025SEC
TNGXTango Therapeutics, Inc.Jan 2, 20257:07 AM ETBCTG Holdings, LLCand 3 others13D/A10.00%10.7M shares–Dec 30, 2024SEC
TYRATyra Biosciences, Inc.Dec 6, 2024Boxer Capital Management, LLC13D/AOld format–––SEC
TYRATyra Biosciences, Inc.Nov 19, 2024Boxer Capital Management, LLC13D/AOld format–––SEC
ITOSiTeos Therapeutics, Inc.Nov 18, 2024Boxer Capital Management, LLC13D/AOld format–––SEC
ITOSiTeos Therapeutics, Inc.Nov 18, 2024Boxer Capital Management, LLC13D/AOld format–––SEC
TNGXTango Therapeutics, Inc.Nov 7, 2024Boxer Capital Management, LLC13D/AOld format–––SEC
TNGXTango Therapeutics, Inc.Oct 28, 2024Boxer Capital Management, LLC13D/AOld format–––SEC
QUREuniQure N.V.Oct 25, 2024Boxer Capital Management, LLC13G/AOld format–––SEC
SWTXSpringWorks Therapeutics, Inc.Oct 25, 2024Boxer Capital Management, LLC13G/AOld format–––SEC
NKTXNkarta, Inc.Oct 25, 2024Boxer Capital Management, LLC13G/AOld format–––SEC
TILInstil Bio, Inc.Oct 25, 2024Boxer Capital Management, LLC13G/AOld format–––SEC
IPSCCentury Therapeutics, Inc.Oct 25, 2024Boxer Capital Management, LLC13G/AOld format–––SEC
FATEFate Therapeutics IncOct 25, 2024Boxer Capital Management, LLC13G/AOld format–––SEC
TYRATyra Biosciences, Inc.Oct 22, 2024Boxer Capital Management, LLC13D/AOld format–––SEC